IP Library Granted Patent US 46,617
Granted Patent E1
US 46,617 · App. 14/743,365 · Granted Nov 28, 2017

Process for making quinolone compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 46,617
App. No.
14/743,365
Granted
Nov 28, 2017
Kind
E1
Abstract

The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.

Claims (22)

1. A process for preparing a quinolone compound comprising the step of reacting a des-chloro quinolone compound or a pharmaceutically acceptable salt or ester thereof with a chlorinating agent and an acid, wherein the molar ratio of the acid to des-chloro quinolone is from about 0.007 0.008 to about 0.02 0.012, and wherein less than about 0.40% 0.35% of dimeric impurity on an area percent basis of the quinolone is produced, wherein the quinolone compound is 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof and the des-chloro quinolone compound is 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-hydroxy-azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof, and wherein the dimeric impurity is 1-amino-3-(azetidin-3-yloxy)-propan-2-ol-bis(N,N′-quinolone carboxylic acid), or a pharmaceutically acceptable salt or ester thereof.

2. A process according to claim 1 wherein the quinolone compound is 1-(6-Amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof and the des-chloro quinolone compound is 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-hydroxy-azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof.

3. A process according to claim 2 wherein the dimeric impurity is 1-Amino-3-(azetidin-3-yloxy)-propan-2-ol-bis (N,N′-quinolone carboxylic acid), or a pharmaceutically acceptable salt or ester thereof.

4. A process according to claim 1 wherein the chlorinating agent is N-chlorosuccinimide.

5. A process according to claim 1 wherein the acid is selected from the group consisting of sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, trifluoroacetic acid, triflic acid, methanesulfonic acid, p-toluene-sulfonic acid, or perchloric acid, and mixtures thereof.

6. A process according to claim 1 wherein the acid is sulfuric acid.

7. A process according to claim 1 where the reaction is run at a temperature from about 0° C. to about 30° C.

8. A process according to claim 1 wherein the molar ratio of N-chlorosuccinimide the chlorinating agent to des-chloro quinolone is greater than about 1.

9. A process according to claim 1 using an acetate ester as a solvent.

10. A process according to claim 9 wherein said acetate ester is selected from the group consisting of methyl acetate, ethyl acetate, and mixtures thereof.

11. A process according to claim 9 wherein said acetate ester is methyl acetate.

12. A process according to claim 1 comprising the further step of reacting the quinolone compound with a base.

13. A process according to claim 12 wherein the base is a hydroxide base.

14. A process according to claim 13 wherein the hydroxide base is selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, and mixtures thereof.

15. A process according to claim 14 wherein the hydroxide base is potassium hydroxide.

16. A process according to claim 12 using a mixture of isopropanol and water as a solvent.

17. A process according to claim 1 wherein said process is a commercial scale process.

18. A composition comprising the quinolone compound 1-(6-Amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof having less than about 0.40% 0.35% of the compound 1-Amino-3-(azetidin-3-yloxy)-propan-2-ol-bis(N,N′-quinolone 1-amino-3-(azetidin-3-yloxy)-propan-2-ol-bis(N,N′-quinolone carboxylic acid), or a pharmaceutically acceptable salt or ester thereof on an area percent basis of the quinolone.

19. A composition according to claim 18 wherein said composition is a commercial scale composition.

20. The process of claim 1 or 2 , wherein the molar ratio of chlorinating agent to des-chloro quinolone is from about 1.05 to about 1.2.

21. The process of claim 1 or 2 , wherein the molar ratio of chlorinating agent to des-chloro quinolone is from about 1.04 to about 1.07.

22. The process of claim 1 or 2 , wherein the molar ratio of acid to des-chloro quinolone is from about 0.008 to about 0.012.

Assignments (8)
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 061314/0572 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 22, 2020
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 054836/0824 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →
RELEASE OF SECURITY INTEREST Recorded Jan 5, 2018
From: SUCHARD SA LLC
To: MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.)
Reel/Frame 044547/0939 →
CHANGE OF NAME Recorded Dec 19, 2017
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 044437/0647 →
SECURITY INTEREST Recorded Jun 28, 2017
From: MELINTA THERAPEUTICS, INC.
To: SUCHARD SA LLC
Reel/Frame 042854/0753 →
CHANGE OF NAME Recorded Dec 20, 2016
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 041033/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2016
From: HANSELMANN, ROGER; REEVE, MAXWELL M.; JOHNSON, GRAHAM
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 040594/0839 →